A Rare Case: Adenocarcinoma Bronchogenic Dextra Std IVB on Gefitinib (15 months) accompanied by Decreased Visual Acuity, Bilateral Sensorineural Deafness and Psychiatric Disorders with No Radiological Evidence of Brain Metastasis

Authors

  • Caesar Ensang Timuda Department of Pulmonology and Respiratory, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
  • Suryanti Dwi Pratiwi Rumah Sakit Syaiful Anwar Malang
  • Dessika Rahmawati Department of Neurology, Saiful Anwar General Hospital, Brawijaya University
  • Dearisa Surya Yudhantara Department of Psikiatri, Saiful Anwar General Hospital, Brawijaya University
  • Dini Rachma Erawati Department of Radiology, Faculty of Medicine, Universitas Brawijaya
  • Dyah Indrasworo Department of Otorhinolaringology, Saiful Anwar General Hospital, Brawijaya University
  • Seskoati Prayitnaningsih Department of Ophtalmology, Saiful Anwar General Hospital, Brawijaya University

DOI:

https://doi.org/10.21776/ub.mrj.2022.004.02.2

Keywords:

-

Abstract

Background: Leptomeningeal disease occurs in 3-5% of patients with lung cancer, mainly adenocarcinoma subtype. Adenocarcinoma is the most common histological finding in Asian women.

Case: A 51-year-old woman with right-sided bronchogenic adenocarcinoma T4N3M1c Std IVB mutation(+) developed decreased vision, severe bilateral sensorineural deafness and psychiatric disorders after receiving Gefitinib 15 months. There was no evidence of brain metastasis from brain MRI. From evaluation of chest CT-scan, we found the disease was progressive and no Mutation Detected from ctDNA, so Gefitinib was discontinued.

Conclusion: We found some difficulties in evaluating side effects of therapy and disease progression due to patient's condition in the form of decreased total vision, severe sensorineural deafness, and psychiatric disorders. However, because no radiological evidence of brain metastases was found, we suspect this patient suffered from leptomeningeal disease.

Keywords: Lung Cancer, Adenocarcinoma, Gefitinib, Leptomeningeal Disease

References

Wistuba I, Brambilla E, Noguchi M, 2018, Classic Anatomic Pathology and Lung Cancer. IASLC. 143-163

Leal, T., Chang, J. E., Mehta, M., & Robins, H. I. (2011). Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Current cancer therapy reviews, 7(4), 319–327. University of Wisconsin Paul P Carbone Comprehensive Cancer

Maemondo, M., Inoue, A., Kobayashi, K., et al, 2010. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. New England Journal of Medicine, 362(25), pp.2380-2388

Nayar, Gautam. Ejikeme, Tiffani. Chongsathidkiet, Pakawat. et all, 2017 "Leptomeningeal disease: current diagnostic and therapeutic strategies", Duke University Medical Center, Durham, NC, USA

Li, Y. S., Jiang, B. Y., Yang, J. J., Tu, H. Y., Zhou, Q., Guo, W. B., Yan, H. H., & Wu, Y. L. (2016). Leptomeningeal metastases in patients with NSCLC with EGFR mutations. Journal of Thoracic Oncology, 11(11), 1962–1969. https://doi.org/10.1016/j.jtho.2016.06.029Niu et al., 2017

Dhawalram Faye, Abhijeet dkk., 2016, Focusing on Psychiatric aspects of cancer: A need of the day?, p117-124

Yu Lee, dkk. 2017. Psychiatric morbidity, Pain, Anxiety and depression in Patient with Head and Neck ang Lung Cancer. IJHNS 2017. p191-198

Mehta, D, 2015, Psychiatric Considerations in the Oncology Setting, American Cancer Society, p299-314

Landrier, Wendy. 2016. Ototoxicity and Cancer Therapy, American Cancer Society, Cancer 2016;122:1647-58

Miller, Neil R., Nancy , J. Newman., Biousse, Valerie. 2005. Walsh & Hoyt's Clinical Neuro-Ophthalmology, 6 th Edition. Philadelphia. p 396- 415

Downloads

Published

2022-09-30

Issue

Section

Case Reports